Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.59 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502527 | 1.00 | GRM5 (0.59) | GRM5P2RX7RAB9ACCR1CCR8 | |
| SCHEMBL321127 | 0.84 | KDM4E (0.59) | GRM5RAB9AKDM4EALOX15TSHR | |
| SCHEMBL2237588 | 0.82 | P2RX7 (0.62) | GRM5P2RX7RAB9ACCR1CCR8 | |
| SCHEMBL1958309 | 0.82 | P2RX7 (0.62) | GRM5P2RX7RAB9ACCR1CCR8 | |
| SCHEMBL118409 | 0.80 | KDM4E (0.70) | GRM5P2RX7RAB9ACCR1CCR8 | |
| SCHEMBL247491 | 0.80 | P2RX7 (0.60) | GRM5P2RX7RAB9ACCR1CCR8 | |
| SCHEMBL9937722 | 0.80 | P2RX7 (0.60) | GRM5P2RX7RAB9ACCR1CCR8 | |
| SCHEMBL29590328 | 0.80 | P2RX7 (0.60) | GRM5P2RX7RAB9ACCR1CCR8 | |
| SCHEMBL1013960 | 0.78 | P2RX7 (0.63) | GRM5P2RX7RAB9ACCR1CCR8 | |
| SCHEMBL9958643 | 0.78 | P2RX7 (0.58) | GRM5P2RX7RAB9ACCR1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| EP-4444728-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | Pretzel Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-12116351-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-10-15 | — | — | US | disclosed |
| US-20240131016-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-1966184-B1 | PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2010-08-25 | — | — | EP | disclosed |
| US-20090306102-A1 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | NEUROSEARCH A/S (DK) | 2009-12-10 | — | — | US | disclosed |
| EP-1966184-A2 | PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008099020-A1 | 1,1-DIOXO-1-THIA-5,10-DIAZADIBENZOCYCLOHEPTENES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008099020-A1 | 1,1-DIOXO-1-THIA-5,10-DIAZADIBENZOCYCLOHEPTENES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2007071632-A2 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | NEUROSEARCH A/S (DK) | 2007-06-28 | — | — | WO | disclosed |
| US-4701461-A | ANTIALLERGENS | USV PHARMACEUTICAL CORPORATION (US) | 1987-10-20 | — | — | US | disclosed |
| US-4632929-A | CARDIOTONIC AGENTS, ANTIALLERGENS | USV PHARMACEUTICAL CORP. (US) | 1986-12-30 | — | — | US | disclosed |
| US-4569941-A | Method of using phenyl-alkylene-2-pyridyl derivatives to increase cardiac contractility in a mammal | USV PHARMACEUTICAL CORP. (US) | 1986-02-11 | — | — | US | disclosed |
| US-4267174-A | AND PROCESS FOR ADMINISTERING | BOEHRINGER MANNHEIM, GMBH (DE) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | GRM5 665/4885P2RX7 3982/4885RAB9A 4491/4885 |
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | LONP1, NLN, ACAT1 | GRM5 3702/4885P2RX7 2775/4885RAB9A 1433/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | GRM5 273/4885P2RX7 1/4885RAB9A 3264/4885 |
| US-12116351-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | GRM5 165/4885P2RX7 1/4885RAB9A 3462/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | GRM5 786/4885P2RX7 1652/4885RAB9A 4538/4885 |
| US-20240131016-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GRM5 2626/4885P2RX7 1103/4885RAB9A 4270/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | GRM5 1693/4885P2RX7 1935/4885RAB9A 4525/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GRM5 2626/4885P2RX7 1103/4885RAB9A 4270/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GRM5 2626/4885P2RX7 1103/4885RAB9A 4270/4885 |
| US-20090306102-A1 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | KCNJ2, KCNQ1, KCNK2 | GRM5 800/4885P2RX7 121/4885RAB9A 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.